Summary
Geographic and ethnic studies of aPL and APS suggest that IgG aCL prevalence may be lower among Afro-Caribbean (Jamaican) SLE patients, who interestingly have a high prevalence of IgA aCL. It is not clear whether this is generalizable to other SLE populations that have African ancestry. Further multi-ethnic studies that are internally controlled for laboratory methods and SLE disease activity would be useful in confirming these reports, and exploring their clinical significance.
Keywords
- Lupus Anticoagulant
- Anticardiolipin Antibody
- Temic Lupus Erythematosus
- Tropical Spastic Paraparesis
- Hughes Syndrome
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, access via your institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Wilson WA, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999;42:1309–1311.
Cucurull E, Espinoza LR, Mendez E, et al. Anticardiolipin and anti-β2glycoprotein I antibodies in patients with systemic lupus erythematosus: comparison between Colombians and Spaniards. Lupus 1999;8:134–141.
Cucurull E, Gharavi AE, Diri E, et al. IgA anticardiolipin and anti-β2glycoprotein I are the most prevalent isotypes in African American patients with systemic lupus erythematosus. Am J Med Sci 1999;31:55–60.
Molina JF, Gutierrez-Urena S, Molina J, et al. Variability of anticardiolipin antibody isotype distribution in 3 geographic populations of patients with systemic lupus erythermatosus. J Rheumatol 1997;24:291–296.
Aguirre V, Cuchacovich R, Barria L, et al. Prevalence and isotype distribution of antiphospholipid antibodies in Chilean patients with systemic lupus erythematosus (SLE). Lupus 2001;10:75–80.
Alarcon GS, Friedman AW, Straaton KV, et al. Systemic lupus erythematosus in three ethnic groups: III A comparison of characteristics early in the natural history of the LUMINA cohort. Lupus 1999;8:197–209.
Jones HW, Ireland R, Senaldi G, et al. Anticardiolipin antibodies in patients from Malaysia with systemic lupus erythematosus. Ann Rheum Dis 1991;50:173–175.
Sebastiani GD, Galeazzi M, Tincani A, et al. Anticardiolipin and anti-β2GPI antibodies in a large series of European patients with systemic lupus erythematosus. Prevalence and clinical associations. European Concerted Action on the Immunogenetics of SLE. Scan J Rheumatol 1999;28:344–351.
Sebastiani GD, Passiu G, Galeazzi M, et al. Prevalence and clinical associations of anticardiolipin antibodies in systemic lupus erythematosus: a prospective study. Clin Rheumatol 1991;10:289–293.
Gourley IS, McMillan SA, Bell AL. Clinical features associated with a positive anticardiolipin antibody in Irish patients with systemic lupus erythematosus. Clin Rheumatol 1996;15:457–460.
Sturfelt G, Nived O, Norgerg R, et al. Anticardiolipin antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 1987;30:382–388.
Alarcon-Segovia D, Deleze M, Oria CV, et al. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. A prospective analysis of 500 consecutive patients. Medicine (Baltimore) 1989;68:353–365.
Shrivastava A, Dwivedi S, Aggarwal A, et al. Anti-cardiolipin and anti-beta2 glycoprotein I antibodies in Indian patients with systemic lupus erythematosus: association with the presence of seizures. Lupus 2001;10:45–50.
Saluja S, Kumar A, Khamashta M, et al. Prevalence & clinical associations of anticardiolipin antibodies in patients with systemic lupus erythematosus in India. Indian J Med Res 1990;92:224–227.
Saxena R, Saraya AK, Dhot PS, et al. Lupus anticoagulant and anticardiolipin antibodies in systemic lupus erythematosus. Natl Med J India 1994;7:163–165.
Ninomiya C, Taniguchi O, Kato T, et al. Distribution and clinical significance of lupus anticoagulant and anticardiolipin antibody in 349 patients with systemic lupus erythematosus. Intern Med 1992;31:194–199.
Wong KL, Liu HW, Ho K, et al. Anticardiolipin antibodies and lupus anticoagulant in Chinese patients with systemic lupus erythematosus. J Rheumatol 1991;18:1187–1192.
Tsutsumi A, Matsuura E, Ichikawa K, et al. Antibodies to β2-glycoprotein I and clinical manifestations in patients with systemic lupus erythematosus. Arthritis Rheum 1996;39:1466–1474.
Chahade WH, Staub HL, Khamashta M, et al. Antiphospholipid antibodies in a Brazilian population with systemic lupus erythematosus. Clin Exp Rheumatol 1989;7:446–447.
Gharavi AE, Pierangeli SS, Wilson WA. Anticardiolipin antibodies: importance, controversies, discrepancies; the need for guidelines and calibrators. Clin Exp Rheumatol 2001;19:237–239.
Wilson WA, Faghiri Z, Taheri F, et al. Significance of IgA antiphospholipid antibodies. Lupus 1998;2(suppl 7):S110–S113.
Perez MC, Wilson WA, Brown HL, et al. Anticardiolipin antibodies in unselected pregnant women. Relationship to fetal outcome. J Perinatol 1991;11:33–36.
Harris EN, Spinnato JA. Should anticardiolipin tests be performed in otherwise healthy pregnant women? Am J Obstet Gynecol 1991;165:1272–1277.
Wilson WA, Morgan Ost C, Barton EN, et al. IgA antiphospholipid antibodies in HTLV-1-associated tropical spastic paraparesis. Lupus 1995;4:138–141.
Faghiri Z, Wilson WA, Taheri F, et al. Antibodies to cardiolipin and beta2-glycoprotein-1 in HTLV-1-associated myelopathy/tropical spastic paraparesis. Lupus 1999;8:210–214.
Murphy EL Jr, De Ceulaer K, Williams W, et al. Lack of relation between human T-lymphotropic virus type I infection and systemic lupus erythematosus I Jamaica, West Indies. J Acquir Immune Defic Syndr 1988;1:18–22.
Rudwaleit M, Tikly M, Gibson K, et al. HLA class II antigens associated with systemic lupus erythematosus in black South Africans. Ann Rheum Dis 1995;54:678–680.
Loizou S, Singh S, Wypkema E, et al. Anticardiolipin, anti-beta(2)-glycoprotein I and antiprothrombin antibodies in black South African patients with infectious disease. Ann Rheum Dis 2003;62:1106–1111.
Hammond MG, Du Toitt ED, Sanchez-Mazas A, et al. HLA in Sub-Saharan Africa: 12th International Histocompatibility Workshop SSAF report. In: Charron D, ed. HLA 1997. Paris: EDK; 1997:345–353.
Wilson WA, Gharavi AE, Piette JC. International classification criteria for antiphospholipid syndrome: synopsis of a post-conference workshop held at the Ninth International (Tours) aPL Symposium. Lupus 2001;10:457–460.
Wilson WA, Gharavi AE. Genetic risk factors for aPL syndrome. Lupus 1996;5:398–403.
Citera G, Wilson WA. Ethnic and geographic perspectives in SLE. Lupus 1993;2:351–353.
Dessein PH, Gledhill RF, Rossouw DS. Systemic lupus erythematosus in black South Africans. S Afr Med J 1988;74:387–389.
Wilson WA, Perez MC, Michalski JP, et al. Cardiolipin antibodies and null alleles of C4 in black Americans with systemic lupus erythematosus. J Rheumatol 1988;15:1768–1772.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Springer-Verlag London Limited
About this chapter
Cite this chapter
Wilson, W.A., Cucurull, E. (2006). Ethnic and Geographic Variation in Antiphospholipid Syndrome. In: Khamashta, M.A. (eds) Hughes Syndrome. Springer, London. https://doi.org/10.1007/1-84628-009-5_21
Download citation
DOI: https://doi.org/10.1007/1-84628-009-5_21
Publisher Name: Springer, London
Print ISBN: 978-1-85233-873-2
Online ISBN: 978-1-84628-009-2
eBook Packages: MedicineMedicine (R0)